Ignyta Investor Information
Ignyta, Inc. is writing a new story for cancer treatment, a story that features our distinctive Rx/Dx strategy to blaze a new path forward for patients.
Our integrated approach combines precision therapeutics with companion molecular diagnostics for the potential benefit of patients with cancer.
Our people work daily to develop meaningful new drugs that target the molecular abnormalities of cancer, allowing us to advance precision therapies to treat each patient’s specific cancer.
We endeavor to eradicate residual disease in precisely defined patient populations by 2030, an audacious goal – backed by the unique combination of delivering the next generation of targeted therapeutics, accompanied by highly informative biomarkers for patient selection, treatment, and monitoring – that makes us confident we can help write the next chapter in the ever-changing story of cancer care.
To stay up to date on all Ignyta investor information, including Press Releases, Stock Information, SEC filings, and more, sign up for Ignyta email alerts.